Healthcare >> CEO Interviews >> April 4, 2011
Dr. Jeffrey Stein, Ph.d., has served as President and CEO of Trius Therapeutics since February 2007, and he has been on the board since 2005. From 2005 through 2007, Dr. Stein was a Kauffman Fellow with the venture capital firm Sofinnova Ventures, Inc. He has also served as a Venture Partner with Sofinnova Ventures since 2007 and as Director of Venture Development for the University of California, San Diego, from 2005 to 2006. From 1999 to 2005, Dr. Stein served as Executive Vice President, Chief Scientific Officer and a Member of the board of Quorex Pharmaceuticals, Inc., an anti-infectives company he founded in 1999, which was acquired by Pfizer Inc. in 2005. From 1995 to 1999 Dr. Stein worked as a Scientist with Diversa Corporation, where he most recently served as Principal Scientist and Head of the anti-infectives discovery team. From 1993 to 1995 Dr. Stein served as Principal Scientist with the Agouron Institute, a private research institution where he conducted research in bacterial genetics. From 1991 to 1993 he was an Alexander Hollander Distinguished Post-Doctoral Fellow with the California Institute of Technology. Dr. Stein earned a Ph.D. in biochemistry and microbiology from the University of California, San Diego. Profile
TWST: Please tell us about Trius Therapeutics and give us a historical background of the company.
Dr. Stein: We are an anti-infectives company, in late-stage clinical development. Our lead program,
